Renaissance Technologies LLC Sells 33,033 Shares of Alumis Inc. $ALMS

Renaissance Technologies LLC trimmed its holdings in Alumis Inc. (NASDAQ:ALMS) by 30.5% in the first quarter, Holdings Channel reports. The institutional investor owned 75,167 shares of the company’s stock after selling 33,033 shares during the period. Renaissance Technologies LLC’s holdings in Alumis were worth $1,656,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Russell Investments Group Ltd. grew its position in Alumis by 320.9% during the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after buying an additional 4,894 shares in the last quarter. New York State Common Retirement Fund increased its stake in Alumis by 173.7% during the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after acquiring an additional 7,467 shares during the period. KBC Group NV acquired a new position in Alumis in the 1st quarter valued at $42,000. Strs Ohio raised its holdings in Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after acquiring an additional 979 shares during the period.

Insider Buying and Selling

In related news, insider David M. Goldstein sold 2,596 shares of Alumis stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $68,456.52. Following the sale, the insider directly owned 30,970 shares of the company’s stock, valued at approximately $816,678.90. The trade was a 7.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Christopher Bradley sold 2,572 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the transaction, the insider owned 48,533 shares of the company’s stock, valued at approximately $1,279,815.21. This represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 19,953 shares of company stock worth $534,311 in the last quarter. Corporate insiders own 33.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ALMS shares. Chardan Capital increased their target price on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, May 19th. Wells Fargo & Company boosted their price target on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Citigroup reissued a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Down 7.8%

NASDAQ:ALMS opened at $25.37 on Wednesday. The stock’s 50-day simple moving average is $25.87 and its 200 day simple moving average is $25.28. The firm has a market capitalization of $3.23 billion, a PE ratio of -12.81 and a beta of -0.69. Alumis Inc. has a twelve month low of $3.76 and a twelve month high of $31.35.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. On average, analysts anticipate that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.